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The purpose of this research project was to examine the voluntary disclosure quality for intellectual 
capital by Australian biotechnology companies between 2003 and 2010. Measurement was made in 
the annual reports of the same 28 biotechnology firms in 2003, 2006 and 2010. Content analysis of 
narrative and measurement items, based on Sveiby’s ‘Intangible Assets Monitor’ categories 
(Internal, External and Human Capital) were used to accurately record the quality of voluntary ICD. 
Although expected, there was no demonstrable increase in the quality of voluntary ICD measured by 
Wilcoxon Signed Rank Test. In fact, the only significant change in quality of ICD reporting in the 
firm’s annual reports was a significant decrease in ‘Internal Capital’ of the type most commonly 
recorded for intellectual property, financial relations and corporate culture. Key success factors for 
‘Human Capital’ ICD, for example staff qualifications and know-how, or ‘External capital’ ICD, like 
those about collaborations, licensing agreements and grant funding, were certainly not absent from 
disclosures, but an expected increase in quality was not detected. A limitation of this study is its 
Australian context. Financial managers’ distraction by 2006 IFRS harmonization (intangible asset 
balance sheet de-recognition) and insulation of the Australian equities market to recent global 
events may partly explain our observation. 
1.1 INTRODUCTION 
Major transformations are taking place in the global economy as historic debt levels and 
instability compete with government recognition about the need for spending on research for 
future development. With this transformation, the fundamental value of firms increasingly 
lies on their intangible assets to generate income. Owning the best infrastructure no longer 
necessarily ensures a competitive advantage as much as the promise of innovative process 
and intellectual property ownership (Wong and Gardner, 2005). The basis of competition 
experienced by firms has shifted from traditional physical and financial resources to 
intangible resources (Khan and Ali, 2010). Intellectual capital (IC) is recognised as a key 
value driver for creating and sustaining competitive advantage for companies (Li et al., 2008; 
Ghosh and Wu, 2007). Examples of successful firms with significant intellectual capital 
abound in the biotechnology sector globally; Johnson & Johnson, CSL, Pfizer and Cochlear, 
to name a few.  
The fear of increasing cost of capital from information asymmetry with investors and lenders 
motivates managers in high-technology or research-intensive firms to make voluntary 
disclosures about intangible firm value and intellectual capital (IC). Investors can choose 
among securities under the assumption that security prices at any time “fully reflect” all 
available information (Fama, 1970). Efficient capital markets theory therefore predicts that 
the information quality of accounting information will redress the adverse selection risk to 
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capital market participants of information asymmetry. In the context of worsening global 
economic debt position stakeholder theory would predict financial reporting sensitivity to the 
balance sheet solvency position and also future debt requirements. 
Intellectual capital disclosures (ICD) by firms are voluntary disclosures about intangible firm 
value are unregulated. Wyatt (2008) explored what financial and non-financial knowledge of 
intangibles is value-relevant for investors. In particular, her review of studies in the area 
categorized the firm’s technological resources as firms’ research and development (R&D) 
expenditure and related intellectual property. Bosworth and Rogers (2001) and Lev and 
Sougiannis (1996) confirm that R&D (i.e. R&D expenditures and patent activity) are 
positively related to a firm’s market value and subsequent stock return. Managers, in their 
quest to obtain a more favourable source of capital, release information regarding R&D 
(amongst other disclosures) and such disclosures have been found to correlate with market-
to-book values of public companies (Deng et al., 1999; Hirschey, 1998; Lev, 2001; 
Brynjolfsson and Yang, 1999). The pre-commercialisation, research and development and 
proof-of-concept activities of biotechnology companies make them a unique industry in 
which to study ICD (White et al., 2010). Equities market regulators in Australia, for example, 
realised the special information asymmetry problems of biotechnology firms’ stakeholders 
and published voluntary intellectual property reporting guidelines to redress this situation 
(ASX, 2005). 
This longitudinal study seeks to divulge the nature and quality of intellectual capital that 
biotechnology companies have been disclosing in their annual reports. In doing so, this study 
hopes to extend the research within the field of voluntary disclosure measurement, especially 
in how it relates to intellectual capital reporting , by examining empirical evidence over the 
period 2003, 2006 and 2010. In the Australian financial reporting context these time points 
are interesting as they rest either before or after some key global and local event which may 
have affected ICD. First 2003 as a base year falls outside the possible distracting effect of 
post-Enron corporate governance reform and reporting. Second, 2003 to 2006 is a period of 
deepening global economic pressures, reducing debt finance availability“Information quality” 
measures the value which the information provides to the user. The importance of a quality 
measure for voluntary intellectual capital disclosures has been gaining traction, with more 
recent studies measuring and discussing quality (see Yi and Davey, 2010).  
The aims of this research, therefore, are to investigate: 
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1. How does the nature of ICD by Australian biotechnology companies change from 
2003 to 2010? 
2. How does the quality of ICD by Australian biotechnology companies change from 
2003 - 2010? 
1.2 MOTIVATION AND SIGNIFICANCE 
The transition towards a knowledge economy brings about significant challenges to the 
accounting profession as current accounting standards do not sufficiently address the 
information needs of stakeholders. The growing prominence of voluntary disclosure in annual 
reports, on company websites and through continuous disclosures to the market is an attempt 
to bridge this gap.  
Corporate disclosures serve as a mechanism for negotiating the relationship between a firm 
and its stakeholders (Gray et al., 1995b) and as a “strategy for managing, or perhaps 
manipulating, the demands of particular groups” (Deegan and Blomquist, 2006, p. 349). With 
the growing awareness of the importance of IC, many managers voluntarily disclose 
information on the intellectual capital of their companies in annual reports to reduce 
information asymmetry and improve transparency between management and various 
stakeholders (Guthrie and Petty, 2000; Pablos, 2002; Schneider and Samkin, 2008; 
Vergauwen et al., 2007). This information gap is very likely to exist in young industries like 
the biotechnology industry, and is the catalyst for a growing body of research on the 
importance of firm intellectual capital and dedicated annual reporting statements (Mouritsen 
et al., 2004; Nielsen et al., 2006). In the past, there have been dedicated studies of intellectual 
capital disclosures by the biotechnology industry. For example, Cerbioni and Parbonetti 
(2007); Cumby and Conrod (2001); Guo et al. (2004), and White et al. (2007, 2010). 
Biotechnology firms have been found to be more likely to report information on intangibles 
since they may have difficulty legitimising their status via the “hard” assets that have 
traditionally symbolised corporate success (Guthrie et al., 2004). Intellectual capital is, 
however, difficult to capture and measure. There is no widely accepted accounting 
framework for IC disclosure around the world and current IC disclosure worldwide is limited 
and highly variable. 
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The academic research interest in the field of ICD reporting practice only started growing in 
prominence in the last decade (Bukh et al., 2005; Guo et al., 2004; Guthrie et al., 2006; 
Kristandl and Bontis, 2007; Vergauwen and van Alem, 2005; Van der Zahn et al., 2007; 
White et al., 2007). Early research-based insight about voluntary ICD practice was obtained 
from companies around 2000 when the Danish guideline for Intellectual Capital Statements 
was developed and tested among a large number of Danish companies (Boedker et al., 2008; 
Bukh et al., 2005; Bukh and Jensen, 2008; Mouritsen and Larsen, 2005; Mouritsen et al., 
2005; Mouritsen, 2004; Nielsen et al., 2006). Early stages of IC accounting research focused 
mainly on the nature of intellectual capital disclosures as an important way of bridging the 
information gap which may exist between managers and firm owners (Eccles and Mavrinac, 
1995). There has been a global trend and demand for more useful and comprehensive non-
financial information about the operating activities of firms (Anderson and Epstein, 1996; 
Global Reporting Initiative, 2011) and specific capital markets research has demonstrated that 
companies need to bridge the information gap between managers and owners, as this can be 
critical to future capital-raising potential (Aboody and Lev, 2000; Barth et al., 2001).  
While studies that investigated the nature of voluntary ICD have been extensive; the quality 
aspect of voluntary ICD has often been overlooked. Contemporary studies have attempted to 
rectify this problem by focussing on quality (Guthrie and Petty, 2000; Oliveira et al., 2006; 
Vandemaele et al., 2005). Financial disclosure is an abstract concept which cannot be 
measured directly (Cooke and Wallace, 1989). Drawing comparisons from the corporate 
social responsibility (CSR) area, it has also been identified that the quantity of disclosure 
does not always equate to quality (e.g. Frost and Wilmshurst, 2000). The quality of ICD 
influences user’s perception of corporate performance, which in turn influences decision 
making. Full disclosure is essential for market efficiency (Fama, 1970).  
This study will extend the current literature by assessing the quality of IC disclosures using a 
quality scale (0-3) for each item in the IC disclosure framework to determine the quality and 
importance of the three categories of IC disclosures: Internal, External and Human Capital. 
Essentially the content analysis measurement is of frequency and then the highest quality of 
disclosure. 
This study contributes to the growing literature on ICD by examining the nature and quality 
of disclosures made by an important sector of a knowledge economy. The results of this study 
will provide an insight into the IC reporting trend of the biotechnology industry and 
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contribute to the extant literature and on overall global view of IC reporting. From a 
normative perspective, managers may also develop a better understanding of historic trends 
in IC disclosure that prescribe changes for improving intellectual capital reporting.   
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2.1 DEFINITION OF INTELLECTUAL CAPITAL 
Existing literature offers a number of definitions of IC (Stewart, 1997; Sveiby, 1997; Petty 
and Guthrie, 2000; Martensson, 2000; Ordonez de Pablos, 2005) with IC as value creators of 
firms (Lynn, 1998). It is agreed that the benefits of IC are accrued over a long period and may 
not be immediately identifiable (ASCPA and CMA, 1999; Brooking, 1997; CMA, 1998; 
Edvinsson, 1997; Edvinsson and Malone, 1998; Edvinsson and Sullivan, 1996; Klein, 1998; 
Knight, 1999; Stewart, 1997; Ulrich, 1998). For this study, IC is defined to include all the 
knowledge-based intangible processes and assets which are not normally shown on the 
balance sheet, and can be leveraged to give rise to future value (Roos et al., 1997). 
2.2 NATURE OF INTELLECTUAL CAPITAL DISCLOSURE 
An easier way to describe IC is by its components (Woodcock and Whiting, 2009). 
Frameworks used to identify intellectual capital have been developed in prior research by 
Bontis (2001), Edvinsson and Malone (1997), Roos et al. (1997), Stewart (1997) and Sveiby 
(1997). Each of these frameworks classifies intellectual capital into components or 
categories, and is used by researchers to identify the nature of intellectual capital disclosure. 
SVEIBY’S (1997) INTANGIBLE ASSETS MONITOR 
Another tripartite framework that was often used in prior ICD studies (Petty and Cuganesan, 
2005) was that originally developed by Karl Erik Sveiby (1997, p. 8-11). Sveiby (1997) 
classified the difference between a firm’s book value and market value as an intangible asset. 
He theorized that this asset is treated as invisible as it lacks a generally accepted definition 
and a measurement standard (Sveiby, 1997). He classified intangible assets into three 
categories, namely:  
 Internal structures (organisational capital); 
 External structures (customer/relational capital); and 
 Employee competence (human capital). 
Intangibles classified under internal structure include items such as patents, concepts, models, 
information systems and anything else within the firm that has a higher value than the value 
of its physical assets (i.e. cost) (Guthrie et al., 1999; Sveiby, 1997; Wong and Gardner, 2005). 
Such intangibles are produced by employees or can be acquired, however, they cannot be 
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taken away from the firm when employees leave at the end of the working day (Guthrie et al., 
1999; Roos et al., 1997; Wong and Gardner, 2005). Organisational culture and spirit are also 
considered part of internal structure, as are organisational structures and legal parameters 
(Sveiby, 1997).  
The external structure includes relationships with customers and suppliers, brand names, 
trademarks and reputation. Some of these can be considered to be proprietary but only in a 
temporal sense and, even then, not with any degree of confidence. These relationships are 
determined by how well a company solves its customers’ problems so there is always an 
element of uncertainty as they can change over time (Sveiby, 1997, p.11). Due to the nature 
of this uncertainty, the economic value of this relationship is at present not determined by any 
generally accepted definition or measurement system (Guthrie and Petty, 2000).  
In a knowledge organisation, the three categories of intangible assets sums the invisible assets 
on the balance sheet as there is little machinery other than employees and, because only 
people can act, employees become both the minders of the machines and the machines 
themselves (Sveiby, 1997). This is an interesting intellectual and academic concept.  
Much research has used Sveiby’s (1997) framework to provide insights into the state of 
intellectual capital disclosure both within countries (Abeysekera and Guthrie, 2005; April et 
al., 2003; Brennan, 2001; Bozzolan et al., 2003; Goh and Lim, 2004; Guthrie et al., 1999; 
Olsson, 2001; Petty and Cuganesan, 2005) and between countries (Guthrie et al., 2006; 
Vandemaele et al., 2005). The principal research method for these studies is content analysis 
of annual reports. In Australia, Guthrie and Petty (2000) are acknowledged as the pioneers in 
applying content analysis to IC reporting by companies.  
Guthrie et al. (1999) did a study for the OECD which looked at the intellectual capital 
disclosure of a sample of Australian annual reports using a modified version of Sveiby’s 
(1997) intangible assets monitor. This modified framework was derived from several 
professional pronouncements on intellectual capital (see IFAC, 1998; CMA, 1998). The study 
involved examining the annual report of each company and coding the information contained 
therein according to a developed framework of intellectual capital indicators.  
Employing the same technique, Guthrie and Petty (2000) modified the framework used in 
Guthrie et al. (1999) to achieve a better convergence with items likely to be reported by 
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Australian companies. The 24 items (nine relating to internal capital, nine to external capital, 
and six to human capital) are shown in Table 1. 
INSERT TABLE 1 
The framework used by Guthrie and Petty (2000) disaggregates voluntary intellectual capital 
disclosures by companies into three categories: 
 Internal Capital; 
 External Capital; and 
 Human Capital. 
A review of the literature revealed external capital as being the most highly disclosed 
category in annual reports. Guthrie and Petty (2000) investigated the disclosure of intellectual 
capital items by Australia’s 19 largest listed companies and one IC best practice company. 
The findings indicated 40% of the sample reported external capital items and reporting of 
both internal capital and human capital categories were evenly matched at 30% each. One 
possible reason for this is “the emphasis in recent years on rationalizing distribution channels, 
reconfiguring firm-value chains, and reaccessing customer value (customer profitability 
analysis etc.)” (Guthrie and Petty, 2000, p. 248). The same finding was again present in 
Guthrie et al.’s (2006) study, which showed that reporting of external capital accounted for 
almost half of the observed reporting practices for the Australian data set; as well as in Goh 
and Lim (2004), where external capital was most disclosed at forty-one percent. One possible 
reason, as suggested in White et al. (2010), was that customer items are reported more and 
customers are a significant stakeholder group for Australian firm managers. April et al.’s 
(2003) findings from studying South African mining companies concurred with that of 
Guthrie and Petty (2000) in that external capital was the most reported category. April et al. 
(2003) attributed the findings to “globalisation pressures and the increasing need for 
companies to focus on external factors such as distribution channels, value chains and 
customer relationships” (April et al, 2003, p. 178) as most emphasis was placed on “business 
collaborations”, “work-related staff competencies”, “management processes”, “customers” 
and “brands” attributes, in the external capital category. In Italy, Bozzolan et al.’s (2003) 
study replicated and extended Guthrie and Petty’s (2000) study by modifying the framework 
slightly after considering the results of the FASB (2001) project. The findings showed 
external structure was reported the most, followed by internal structure and then human 
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capital. Their findings on the average amount of disclosure also concurred with Guthrie and 
Petty’s (2000) study that there is an awareness of the importance of intellectual capital 
variables (Bozzolan et al., 2003). Vandemaele et al. (2005) used Bozzolan et al.’s (2003) 
classification framework when examining the annual reports of companies in the 
Netherlands, Sweden and the UK in a longitudinal study. They too, found that an increased 
number of firms are disclosing more about external structure, compared to the other two IC 
categories. 
Vandemaele et al.’s (2005) results showed on average that the Dutch, Swedish and UK 
sample companies had a significant increase in their IC disclosures over the period 1998-
2000, however a non-significant increase was observed in the 2000-2002 period. Vandemaele 
et al. (2005) suggested that the slow-down in the upward trend in IC disclosure might be 
because companies have met the information need of investors with respect to IC and the 
potential cost for disclosing more IC might hurt the competitive situation of a company for 
example; therefore acting as a disincentive for companies to disclose more. However, studies 
conducted in other countries found contrary results. Abeysekera and Guthrie (2005) 
compared intellectual capital reporting frequency of the top 30 firms listed on the Colombo 
Stock Exchange in the time period between 1998/1999 to 1999/2000. The results of the 2-
year study indicated that firms in Sri Lanka reported an overall increase in disclosure in all 
categories of intellectual capital. Petty and Cuganesan (2005) examined the voluntary 
intellectual capital disclosure by listed Hong Kong companies and they too found that while 
disclosure levels were low, it was increasing over time. 
Guthrie and Petty (2000) found that there was no consistent framework for firms to disclose 
their IC in Australia. Few companies appear to be proactive in measuring and reporting their 
IC to their stakeholders, although most of them have realized the growing importance of IC 
for their future success. The findings of subsequent studies have supported Guthrie and 
Petty’s (2000) findings (e.g Bozzolan et al., 2003; Wong and Gardner, 2005; Shareef and 
Davey, 2006; Schneider and Samkin, 2008).  
Guthrie et al. (2006) compared the levels of IC disclosures in Hong Kong and Australia using 
a modified version of the framework based on Guthrie and Petty (2000). The framework was 
modified differently for the two geographical contexts. The elements in the IC framework for 
the Australian study were slightly modified to account for recent developments in the 
country. This resulted in a total of 18 IC attributes being investigated in the Australian study. 
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For the Hong Kong study, a total of 27 IC attributes were investigated. This was to account 
for the work of Bozzolan et al. (2003) and others in extending the classification schema used 
in Guthrie and Petty (2000). A finding in Guthrie et al.’s (2006) study was that the reporting 
of IC was inconsistent and varied in nature between different countries. The Hong Kong 
dataset showed IC disclosure to be evenly split amongst the three categories of IC, however 
the Australia dataset showed external capital was the most frequently reported with human 
capital reported the least. 
Accordingly, the following null hypothesis is proposed: 
Hypothesis 1: There is no change in the nature of IC disclosure over the years 2003 
– 2010. 
2.3 QUALITY OF INTELLECTUAL CAPITAL DISCLOSURE 
Petty and Cuganesan (2005) highlighted that future research in intellectual capital disclosure 
studies could focus on the quality of disclosure in annual reports in order to extend current 
research. However, while extensive research has been done with regards to the nature of 
intellectual capital disclosures, the quality aspects of it has been under-represented in the 
literature. Yi and Davey (2010) reviewed previous research in IC disclosure and whether any 
measure of quality was included in their research. It was noted that while a lot of prior studies 
looked into intellectual capital disclosures using the many frameworks available, studies 
generally failed to measure the quality of intellectual capital disclosures (see Yi and Davey, 
2010).  
Studies conducted in different continents have consistently found IC disclosure quality to be 
low. In particular, Yi and Davey (2010) found the average disclosure quality of IC by 49 
mainland China companies to be at 0.44
1
, with two thirds of the companies scoring below 
0.5. The average quality score for each category of intellectual capital (internal, external and 
human capital) was below 0.50. The low quality scoring indicates that most of the reported 
attributes were expressed in narrative rather than numerical or monetary terms (which would 
have been indicated by a higher scoring). Guthrie et al. (2006), in their study of intellectual 
capital disclosure in Hong Kong and Australia, revealed that nearly every instance of 
intellectual capital reported was in narrative rather than numerical terms, which was similar 
                                                          
1
 Average disclosure quality out of a maximum of 1. 
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to the findings in Ireland by Brennan (2001). There is a general consensus in the studies 
reviewed that the low-quality scoring in research to date (Bozzolan et al., 2003; Shareef and 
Davey, 2006; Schneider and Samkin, 2008; Wong and Gardner, 2005) is because there is no 
established and generally accepted framework to quantify IC information (Guthrie and Petty; 
2000; Guthrie et al., 2006; Yi and Davey 2010), and any quantification might give rise to 
inaccurate meaning (Abeysekera and Guthrie, 2005; Guthrie et al., 1999). 
The demand for greater disclosure of information by companies has a number of drivers: the 
post-Enron desire for trust and transparency; “audit society”; the changing nature of value; 
internet and the growing “corporate social responsibility” agenda (Bezhani, 2010). 
Specifically in Australia, the onset of the global financial crisis as well as funding cuts by the 
federal government had severely affected the fund-raising capabilities of the Australian 
biotechnology companies (Biotech Business; Global Financial Crisis Making Biotech 
Business Model Unsustainable, According to Ernst & Young; May 20, 2009; Robertson, 
2009). In an increasingly competitive market, where funding is getting harder to come by, 
non-financial disclosures can have a positive impact on management creditability, analysts’ 
understanding, and investors’ patience over poor performance (Eccles and Mavrinac, 1995). 
Guthrie et al. (2004) argued that firms are more likely to report information on intangibles if 
they cannot legitimise their status via the “hard” assets that traditionally had symbolised 
corporate success. This would suggest that the quality of IC disclosure would be higher for 
the biotechnology industry since “biotechnology companies are a fascinating example of 
firms with intangible value” (White et al., 2007, p. 517) as more than half of the listed 
Australian biotechnology firms are actively engaged in research and development-only 
activities (White et al., 2007). Similarly, Bruggen et al. (2009) as well as Kamath (2008) have 
found that industries, specifically the high-technology industries, that rely more on 
intellectual capital, disclose more information on IC. 
The post-Enron era, the subsequent onset of the global financial crisis, and the continuing 
global recession have left investors and the public devastated and sceptical of those left in 
charge. Increasingly, the public and investors are seeking more information pertaining to the 
operating activities of the companies above and beyond those required by legislation. The 
fear of increasing cost of capital from information asymmetry with investors or lenders 
motivates managers to make voluntary disclosures about intangible firm value like its 
intellectual capital (IC) (Jensen and Meckling, 1976). The literature has suggested that the 
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quality of intellectual capital disclosure is expected to remain low because there is no 
established framework for intellectual capital reporting. This study hypothesizes that the 
quality of IC disclosure by Australian biotechnology firms will improve over the years due to 
recent events (Anderson and Epstein, 1996; Bezhani, 2010; Global Reporting Initiative, 
2006) and findings from prior research (Bruggen et al., 2009; Guthrie et al., 2004; Kamath, 
2008). 
Accordingly, the following null hypothesis is proposed: 
Hypothesis 2: There is no change in the quality of IC disclosure over the years 2003 
– 2010. 
2.4 LOCATION OF INTELLECTUAL CAPITAL DISCLOSURES 
Guthrie et al. (2004) established that meaningful accounting studies investigating quality of 
IC disclosure had to examine the reporting theme, the form of disclosure, and the location of 
the disclosure to yield meaningful results. This can be achieved by examining the relative 
emphasis on each theme, whether the disclosure was quantified or not, and the location of the 
disclosure (Guthrie et al., 2004). Guthrie et al. (2006), in their study of Hong Kong and 
Australian firms, divided the annual reports into five sections: 1) the vision/strategy section; 
2) the director’s section; 3) the business/operational section; 4) the financial section; and 5) 
the “other” sections. Their findings showed IC elements were most widely reported in the 
“business/operational” section of the annual report with nearly half of all reporting in that 
section. The “other” section, which included any items that did not fit into the classification 
of the remaining sections, was the second most popular with nearly one quarter of all IC 
items disclosed in that location. The least amount of disclosure was in the financial section. 
This is as expected since there are no corporation laws or accounting standards that require 
the quantification of IC. This approach provides a description of the disclosure practices of 
organisations (Guthrie et al., 2004). 
This study also measured the location of the highest quality voluntary ICD made by 
biotechnology firms. 
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3.1 RESEARCH METHODS 
Content analysis of annual reports was adopted as the primary research method. As an 
instrument for data collection, content analysis involves codifying qualitative and quantitative 
information into pre-defined categories based on selected criteria in order to derive patterns 
in the presentation and reporting of information (Guthrie et al., 2004). The 2003, 2006 and 
2010 annual reports from 28 Australian biotechnology companies (listed on the Australian 
Stock Exchange) were the original objects of study from which voluntary ICD data were 
collected. Voluntary ICD in the companies’ annual reports were analysed using the 
framework developed by Guthrie and Petty (2000). Guthrie et al. (2006) re-modified the IC 
framework to account for recent developments in Australia as well as the work of other 
researchers. The items are listed in Table 2. 
INSERT TABLE 2 
3.1.1 QUALITY OF INTELLECTUAL CAPITAL DISCLOSURE 
Some researchers criticised that a number is not necessarily worth more than a comment 
(Marston and Shrives, 1991). This is because a qualitative discussion might provide the 
reader with a better understanding of the topic at hand while providing a set of numbers by 
itself might not necessarily have the same effect. Nevertheless, Botosan (1997) argues that 
quantitative information is more precise and therefore more useful to readers of annual 
reports. This study examined the degree of IC disclosure in the annual reports of 
biotechnology companies, whether it had been quantified, and, in the process determine the 
quality of ICD in the biotechnology industry. 
Previous studies have assessed the quality of IC disclosure using differing quality criteria 
scales. For instance: a six point scale (0-5, 5 for quantitative/monetary disclosure with 
narrative; 4 for quantitative/monetary disclosure; 3 for narrative disclosure; 2 for obscure 
disclosure; 1 for immaterial disclosure and 0 for non-disclosure) was used by Schneider and 
Samkin (2008), Shareef and Davey (2006), and Yi and Davey (2010); a four point scale (0-3, 
3 for monetary disclosure; 2 for numerical disclosure; 1 for narrative form and 0 for non-
disclosure) was used by Guthrie et al. (1999) and Guthrie et al. (2006); a three point scale (0-
2, 2 for quantitative disclosure; 1 for qualitative disclosure and 0 for non-disclosure) was 
used by Bozzolan et al. (2003) and Wong and Gardner (2005); and a two point scale (0-1, 1 
for disclosure and 0 for non-disclosure) was used by Brennan (2001), Bontis (2003), Goh and 
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Lim (2004), and Abeysekera and Guthrie (2005). The six point scale is the most 
comprehensive, allowing more discrimination when assessing the quality of disclosure. 
Studies using this scale identified some IC items which were narrative in nature and were 
problematic and impractical to assign quantitative or monetary value to. Shareef and Davey 
(2006) identified three items, namely “technological process”, “management process” and 
“company names/ground names”, while Yi and Davey (2010) identified “management 
philosophy/corporate culture”, “work-related knowledge”, and “entrepreneurial spirit” as 
items that were only disclosed in the narrative form. Based on these two prior studies 
(Shareef and Davey, 2006; Yi and Davey, 2010) these items were assigned a maximum score 
of three (narrative disclosure) when collecting data in this study. In addition, studies by 
Guthrie et al. (1999) and Guthrie et al. (2006), both found that IC items that were disclosed 
were expressed in narrative rather than numerical terms. Therefore, based on the literature 
reviewed, it was concluded that a four point (0-3) scale would be sufficient to capture the 
quality of IC disclosure in annual reports and ensure the reliability of the results.   
In this study, a value of zero (0) was assigned if the variable did not appear in the annual 
report; a value of one (1) if the variable appeared in narrative form; a value of two (2), if the 
variable was expressed in specific (numerical) terms; and a value of three (3), if the variable 
was quantified in dollar terms (refer to Table 3).  
INSERT TABLE 3 
Some items in the framework could only be given a maximum score of one (1) due to its 
narrative nature. These items were “Management philosophy”, “Corporate culture”, 
“Management processes” in the internal capital category; “Company names” in the external 
capital category; and “Work-related knowledge”, “Entrepeurial spirit” in the human capital 
category. After thoroughly reviewing all of the text in approximately ninety annual reports 
during the scoring process, it was discovered that there were no possible numerical or 
monetary form of disclosures. Therefore, with this reflection and logical reasoning that it 
could not be foreseen how any might even be possible, the above mentioned items were given 
a maximum score of one (1). 
3.1.2 LOCATION OF INTELLECTUAL CAPITAL REPORTING IN THE ANNUAL REPORTS 
Guthrie et al. (2004, p.289) stated that “studying the quality of disclosure by examining the 
relative emphasis on each theme, whether the disclosure is quantified or not, and the location 
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of disclosure is the approach mostly likely to yield meaningful results”. This approach not 
only provided a description of the disclosure practices of organisations, but also identified the 
key issues that needed to be focused on in subsequent in-depth investigations on how these 
organisations identify, measure, and report their IC (Guthrie et al., 2004). 
As such, this study built on the five sections originally used by Guthrie et al. (2006) and 
divided the annual reports into the following seven sections:  
INSERT TABLE 4 
3.1.3 DATA CAPTURE 
To ensure the reliability of the data collected, two coders were employed for consistency. The 
method that was employed was for one coder to read the annual reports, identify and record 
information related to each item of the ICD index onto a coding sheet. For each of the items 
data was gathered and recorded in terms of: 1) quality of data, and 2) location. A second 
coder randomly checked the data collected to ensure consistency in the coding process.  
3.1.4 CONTROL VARIABLES 
Positive Accounting Theory (PAT) predicts that managers will monitor and attempt to reduce 
information asymmetry with investors and lenders for fear of increasing cost of capital by 
making voluntary disclosures about intangible firm value, such as its intellectual capital (IC), 
to bridge that knowledge gap (White et al., 2010). PAT also predicts such positive disclosure 
practices might be predicted if the firm was attempting to minimise the greater political costs 
associated with large companies. Therefore in this study, market capitalisation was used as a 
proxy for size whereas leverage was used to reflect the significant obligations that managers 
have under existing debt covenants.  
3.1.4.1 COMPANY SIZE 
As Foster (1986, p.44) states, “the variable most consistently reported as significant in studies 
examining differences across firms in their disclosure policy is firm size” (Chow and Wong- 
Boren, 1987; Cooke, 1989; Hossain and Adams, 1995; Meek et al., 1995; and Watson et al., 
2002). A review of the literature identified studies examining IC disclosure practices 
controlling for company size using various proxies such as market capitalization (Guthrie et 
al., 2004; Petty and Cuganesan, 2005), sales (Bozzolan et al., 2003; Cordazzo, 2007) and 
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number of employees (Bukh et al., 2005). This study uses market capitalisation as a proxy for 
size as listed companies will have this information readily available in their annual reports. 
Moreover, most Australian biotechnology companies are actively engaged in research and 
development-only activities (White et al., 2007) and therefore are more reliant on 
shareholders for much of their financing needs. It is, therefore, expected that larger firms will 
report higher quality and more intellectual capital disclosures due to the greater resources 
available to them in conducting research and development and for reporting subsequent IC.  
3.1.4.2 COMPANY LEVERAGE 
Traditional agency theory predicts that highly leveraged firms have significant obligations 
under existing debt covenants and incur monitoring costs to achieve equilibrium between 
self-interested managers as agents for external debt-holders (Dhaliwal et al., 1982). Watts and 
Zimmerman (1986) further explained that as organisations employ more external financing, 
management are more likely to attempt to use different policies for their own benefit. This 
study used the level of company’s leverage (total balance sheet liabilities divided by total 
assets) as a proxy to reflect the obligations that managers had under existing debt covenants 
to voluntarily disclose IC. A positive correlation between firm leverage and voluntary 
segment disclosures was found by Bradbury (1992) while no relationship was found between 
the same two variables measured in New Zealand firms (Chow and Wong-Boren, 1987). 
However, White et al. (2007) found strong evidence in Australian biotechnology companies 
that leverage was found to be a significant driver in biotechnology companies’ voluntary IC 
disclosure. Therefore, because of the leverage effect on intellectual capital disclosures, this 
study will control the leverage effect on intellectual capital disclosures in order to study the 
trend of intellectual capital disclosure. 
3.1.5 DATA COLLECTION 
When scoring each annual report, information pertaining to the quality of intellectual capital 
disclosed as well as the location of the disclosure was recorded onto a scoring sheet (See 
Appendix 2). As mentioned previously, random checks were conducted to ensure coding 
consistency. Information from the coding sheets was then transferred into a spreadsheet for 
further data analysis. The raw scores for each year were recorded as follows: 1) the nature of 
ICD; 2) the quality of ICD; and 3) the location of ICD.  
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Data pertaining to the market capitalisation and level of company’s leverage were sourced 
from the  FinAnalysis database. The market capitalisation and leverage data for 2003, 2006 
and 2010 for each company were collected and inputted into a spreadsheet.   
3.1.6 DATA ANALYSIS 
In this study, the distribution of the data collated was not normally distributed; skewness and 
kurtosis were high and because of this non-parametric statistics were used. IBM’s SPSS 
(Version 19) software was used for statistical analysis of the data. In order to test for any 
significant relationships between the variables, Spearman’s Rank Correlation Coefficient was 
run to determine the correlations between the variables in each year. Mann-Whitney U tests 
were performed to test if leverage and market capitalisation had a significant effect on the 
quality of the disclosed intellectual capital categories. Lastly, Wilcoxon Signed Rank Tests 
were performed to determine if there were any significant change in intellectual capital 
disclosure quality between years. 
In order to show the reporting trend of intellectual capital disclosure in the annual reports, 
data collected pertaining to the location of IC disclosed for each year was summed. The total 
count of ICD in each section of the annual reports for each year was computed as a 
percentage of the total count in that particular year. The percentage count for each section 
was then used to identify where IC was primarily disclosed for each year and compared 
amongst the years to present a reporting trend. 
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Over the 2003 – 2010 period, biotechnology companies sampled in this study disclosed all 
three aspects of intellectual capital, however, the frequency of disclosure varied greatly 
among these three categories. The results for 2003 (Table 5.1), 2006 (Table 5.2) and 2010 
(Table 5.3) show that the sampled biotechnology companies reported external capital 
disclosures most frequently at 48 per cent for 2003, 44 per cent for 2006, and 49 per cent. 
Human capital was the least reported category for disclosure, accounting for only 15 – 16 per 
cent of total discourse in any one year. Internal capital disclosures accounted for 37 per cent 
of total disclosure in 2003, 40 per cent in 2006, and 35 per cent in 2010 (refer to Tables 5.1, 
5.2 and 5.3). 
4.2 INDIVIDUAL ATTRIBUTE FINDINGS 
The individual attribute findings reported in this section relates to the items in the disclosure 
framework that were used in this study. The disclosure frequency of each different quality of 
disclosure for each IC item is shown in Tables 5.1, 5.2 and 5.3. 
4.2.1 INTERNAL CAPITAL ATTRIBUTES 
In the internal capital category (refer to Tables 5.1, 5.2 and 5.3), “Corporate culture” (item 
1.3) was the most frequently reported internal capital item as it was reported by 19 companies 
out of 28 in 2003 (refer to Table 5.1), and was fully disclosed by all companies in 2006 and 
2010 (refer to Tables 5.2 and 5.3). The least reported item “Information/networking systems” 
(item 1.5), was only reported by less than 3 companies in any of the years studied.  
Comparing the frequency of reporting internal capital items over the years, “Intellectual 
Property” (item 1.1), “Corporate culture” (item 1.3), and “Financial relations” (item 1.6) 
constantly had a relatively higher frequency of disclosure among the internal capital items. 
4.2.2 EXTERNAL CAPITAL ATTRIBUTES 
In the external capital category (refer to Tables 5.1, 5.2 and 5.3), “Brands” (item 2.1) was the 
most frequently reported external capital item, being reported by no less than 26 companies 
in any period. The least reported category item was “Customer loyalty” (item 2.3) with less 
than 5 companies reporting it in any one period. The frequency of reporting external capital 
items over the years showed “Brands” (item 2.1), “Customers” (item 2.2), “Company names” 
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(item 2.4) and “Business Collaborations” (item 2.6) as being the items that had a relatively 
higher frequency of disclosure among the external capital items.  
INSERT TABLE 5.1 
4.2.3 HUMAN CAPITAL ATTRIBUTES 
In the human capital category (refer to Tables 5.1, 5.2 and 5.3), the only item that was 
disclosed by all companies in the three reporting periods was “Know-how” (item 3.1). 
“Education” (item 3.2) was not disclosed in any of the three reporting periods while the 
remaining items were irregularly reported with a low quality score. 
INSERT TABLE 5.2 
INSERT TABLE 5.3 
4.3 DESCRIPTIVE STATISTICS ON THE QUALITY OF INTELLECTUAL CAPITAL 
CONTENT IN THE ANNUAL REPORTS 
4.3.1 DISCLOSURE QUALITY FOR 2003 
As the distribution of the data pertaining to the quality of intellectual capital disclosure that 
was collated was not normal, it was more suitable to use the median to compare the 
intellectual capital disclosure quality score for IC (internal capital), EC (external capital), and 
HC (human capital). For the 2003 data set, the median disclosure quality scores for internal 
capital, external capital and human capital were 0.58, 0.42 and 0.18, respectively. The gap in 
disclosure quality between the three categories is 0.4 with scores of 0.58 for internal capital 
(the highest score) to 0.18 for human capital (the lowest score). The median for market 
capitalisation was AU$21.1 million, with the largest company in the sample having a market 
capitalization at 30 June 2003 of AU$512.5 million and the smallest with AU$3.1 million 
market capitalisation. The median leverage score of the sample companies was 0.15. The 
highest level of firm leverage recorded in the sample was 0.52 and the lowest at 0.01. These 
descriptive statistics are presented in Table 6.1. 
INSERT TABLE 6.1 
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4.3.2 DISCLOSURE QUALITY FOR 2006 
Likewise for the 2006 data set, the median disclosure quality scores for the three categories of 
voluntary intellectual capital disclosure were 0.42, 0.32 and 0.18 for internal capital (IC), 
external capital (EC) and human capital (HC) respectively. The gap in disclosure quality 
between the three categories is 0.24 with scores of 0.42 for internal capital (the highest score) 
to 0.18 for human capital (the lowest score). The median for market capitalisation was 
AU$22.1 million, with the largest company in the sample having a market capitalization at 30 
June 2006 of AU$377.8 million and the smallest with AU$3.7 million market capitalisation. 
The median leverage score of the sample companies was 0.16. The highest level of firm 
leverage recorded in the sample was 1.27 and the lowest at 0.31. These descriptive statistics 
are presented in Table 6.2. 
INSERT TABLE 6.2 
4.3.3 DISCLOSURE QUALITY FOR 2010  
For the 2010 data set, the median disclosure quality scores for the three categories of 
voluntary intellectual capital disclosure were 0.42, 0.37 and 0.18 for internal capital (IC), 
external capital (EC) and human capital (HC) respectively. The gap in disclosure quality 
between the three categories is 0.24 with scores of 0.42 for internal capital (the highest score) 
to 0.18 for human capital (the lowest score). The median for market capitalisation was 
AU$12.7 million with the largest company in the sample having a market capitalization of 
AU$264.4 million and the smallest with AU$2.1 million market capitalisation at 30 June 
2006. The median leverage score of the sample companies was 0.23. The highest level of 
firm leverage recorded in the sample was 5.98 and the lowest was 0.07. These descriptive 
statistics are presented in Table 6.3. 
INSERT TABLE 6.3 
4.3.4 CORRELATION MATRIX ANALYSIS 
Tables 7.1, 7.2 and 7.3 present a correlation matrix reporting non-parametric Spearman’s 
rank coefficients for the ranked variables used in this study for the years-ending 2003, 2006 
and 2010. 
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A significant positive relationship was observed between the quality of human capital 
disclosure and internal capital disclosure (r = 0.40, p = 0.03), and human capital disclosure 
and external capital disclosure (r = 0.49, p = 0.01) in the 2003 data set (see Table 7.1). 
However, the same relationship was not observed in the 2006 or 2010 data sets (see Tables 
7.2 and 7.3 respectively). 
No significant correlation was found between the quality of any intellectual capital disclosure 
and firm size or amount of leverage in any of the data sets (refer to Tables 7.1, 7.2 and 7.3). 
INSERT TABLE 7.1 
INSERT TABLE 7.2 
INSERT TABLE 7.3  
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A review of Tables 7.1, 7.2 and 7.3 showed the maximum correlation between variables were 
not above the critical multicollinearity limit of 0.8 (Hair et al., 1995). There was no 
significant correlation between the quality of different intellectual capital categories (IC, EC 
and HC) and size (market capitalisation) over the period studied. This is an interesting 
finding because it is contrary to the significant effect of size on the frequency of measured IC 
disclosure in past studies(Abdolmohammadi, 2005; Bozzolan et al., 2003; White et al., 2007).  
 
Similarly, there was no significant correlation between the quality of different intellectual 
capital categories (IC, EC and HC) and leverage over the period studied. This was contrary to 
other ICD studies where leverage was found to have a significant influence on the frequency 
of IC disclosure (Bradbury, 1992; White et al., 2007). The results of this study appear to 
complement and extend other researchers’ findings in that significant increases in frequency 
of ICD by larger companies, or in response to increased leverage, may not correlate with 
high-quality disclosure. 
4.3.5 LONGITUDINAL ANALYSIS OF QUALITY OF INTELLECTUAL CAPITAL 
DISCLOSURE 
In order to determine if there were any significant differences in the quality of intellectual 
capital disclosures over time, Wilcoxon Signed Rank Test was used. The results are presented 
in Tables 8.1, 8.2 and 8.3.   
4.3.5.1 INTERNAL CAPITAL 
The results of the Wilcoxon Signed Rank Test indicated that there was a significant 
difference in the quality of internal capital disclosures for the same companies between 2003 
and 2006, as well as between 2003 and 2010. However, this was not noted for 2006 and 
2010. The results are presented in Table 8.1 below.  
INSERT TABLE 8.1 
Comparing the 2003 and 2006 internal capital quality scores, it was found that 16 companies 
had higher internal capital scores in 2003, 6 companies had a higher quality score in 2006 and 
the remaining 6 had no change in the quality of disclosure (refer to Table 8.1). Comparing the 
2003 scores with the 2010 scores, it was found that 18 companies had higher quality scores in 
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2003, 6 companies had a higher quality score in 2010, while 4 companies did not change the 
quality of their disclosure. 
4.3.5.2 EXTERNAL CAPITAL 
There was no significant differences found in the quality of external capital disclosures for 
the companies between 2003/06, 2006/10 or 2003/10 (refer to Table 8.2). 
INSERT TABLE 8.2 
While the results showed no significant change in the quality of external capital disclosure 
over the years, an interesting observation is that the disclosure of external capital information 
over the period 2003 – 2010 had actually decreased in quality. Of the total sample 19 
companies had a higher quality of disclosure in 2003 than they did in 2010, with only 9 
companies having reported higher quality external capital information in 2010. 
4.3.5.3 HUMAN CAPITAL 
No significant differences were found in the human capital category quality scores for the 
periods that were studied (refer to Table 8.3). 
INSERT TABLE 8.3 
While there is no significant change in the quality of human capital disclosure over the years, 
the results of this test showed 9 companies reporting higher quality information pertaining to 
human capital in 2003 as compared to 2010, with 6 companies reporting lower quality 
information. However, 13 companies were found to have no change in the quality of human 
capital disclosure. 
4.4 LOCATION OF INTELLECTUAL CAPITAL DISCLOSURES 
To measure the location of intellectual capital disclosures the annual report was divided into 
seven locations, namely Vision/Strategy (1), Director’s Report (2), Business/Operational 
section (3), Financial statements and notes (4), Chairman’s letter (5), CEO’s letter (6) and 
Others (7). Tables 9.1, 9.2 and 9.3 present the descriptive statistics with regards to the 
location of intellectual capital disclosures for each year. The total counts of disclosure for 
each year ranged from 632 in the 2010 data set (lowest) to 757 in the 2003 data set (see 
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Tables 9.1, 9.2 and 9.3). A review of Tables 9.1 to 9.3 showed consistency in the disclosure 
location of ICD in 2003, 2006 and 2010, respectively. 
INSERT TABLE 9.1 
Table 9.1 shows that more than half of the total IC disclosures in 2003 can be found in the 
Director’s Report and Business/Operational sections of the annual reports (29.06% and 
26.16%, respectively). This was consistent in the 2006 and 2010 data sets, with a total 
percentage of 65.79% and 45.72% disclosed in 2006 and 2010 (see Tables 9.2 and 9.3, 
respectively). 
INSERT TABLE 9.2 
INSERT TABLE 9.3 
The least amount of disclosure was in the Vision/Strategy section, accounting for no more 
than 1% of total counts recorded in any one year. This was expected, since only disclosures 
relating to visions and strategies would typically be disclosed in that section (see Tables 9.1, 
9.2 and 9.3). A fair amount of intellectual capital disclosure was found in the Chairman’s 
letter and CEO’s letter sections of the annual report, with a total of 18.36% in 2003; 16.50% 
in 2006; and 19.78% in 2010. This was a surprising result as these two sections were 
typically short sections when compared to the other sections in the annual report. 
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5.1 DISCUSSION AND IMPLICATIONS OF RESULTS 
Using content analysis of annual reports of a sample of Australian biotechnology companies 
(n=28), the nature and quality trend of IC disclosure were investigated. The study used data 
from the same 28 firms over a seven year period. In total, a content analysis of 84 corporate 
annual reports was measured over the years 2003, 2006 and 2010.  
5.1.1 NATURE OF INTELLECTUAL CAPITAL DISCLOSURE 
The descriptive data presented in Table 5.1 (2003), Table 5.2 (2006) and Table 5.3 (2010) 
record the frequency and maximum level of quality disclosed in each of the 28 biotechnology 
companies’ annual reports. Two interesting observations are possible. The first results 
showed that external capital is the most frequently disclosed category of intellectual capital in 
all of the three periods when management annual reporting disclosure were measured. 
Narrative disclosures about brand, customers, company names and business collaborations 
were frequently disclosed components (items) of external/relational capital; the most 
disclosed category of intellectual capital. This findings was consistent with leading prior 
research in the field (April et al., 2003; Bozzolan et al., 2003; Guthrie and Petty, 2000; 
Guthrie et al., 2006). A clear pattern emerged that external capital was the most frequently 
disclosed category of intellectual capital, followed by internal capital and, lastly, human 
capital. 
The above findings are very novel in that a longitudinal examination of this type, measuring 
categories of intellectual capital disclosed by the same biotechnology firms over time, has not 
been done before. An interesting implication of this result is that, over the time period 
studied, the categories of intellectual capital chosen to be disclosed by firm managers is yet to 
reflect what might be expected in an academic sense from firms in the industry. For example, 
if the concept of intellectual capital is contextualized within this industry and especially if 
key success factors for Biotechnology are incorporated in the reflection, then the following 
intellectual capital disclosures should be high quality and frequent: 1) R&D disclosures about 
firm intellectual property; 2) R&D disclosures about firm collaboration; 3) R&D disclosures 
about strategic alliances with research partners; 4) licensing disclosures about successful 
exploitation of intellectual property; 5) Knowledge disclosures about scientific qualifications 
of executives; 6) Knowhow disclosures about processes; and, 7) R&D disclosures from non-
reciprocal revenue recognition issues when grant income is spent. The above synopsis 
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indicates an expectation that internal and human capital disclosure frequency would both be 
greater for these companies. Therefore it appears that preparers of non-financial information 
in Australian biotechnology companies at least may have a skewed focus towards reporting 
on external capital components compared with those expected by the equities market, relating 
to internal and human perspective and their key success factors. 
From analysing the intellectual capital items chosen to be disclosed by firm managers, 
specific items were identified to be consistently disclosed more often than the rest, across the 
years studied. The specific emphasis placed on the disclosure of these items might indicate 
the importance managers’ place on intellectual capital reporting. However, the lack of 
attempt to further intellectual capital reporting in their annual reports (i.e. by disclosing other 
items) and the skewed focus towards reporting on external capital components suggest that 
the discussion on IC as it takes place in academia, has not yet found its way to corporate 
Australia in this industry sector (Vergauwen and van Alem, 2005). Current disclosure 
practise is ad-hoc and illustrates a picture of managers having a limited knowledge of the 
topic of intellectual capital as well as possibilities for increasing communications to the 
market with it. In other words, information asymmetry identified between managers and 
investors in this high-technology industry does not appear redressed over time. 
5.1.2 QUALITY OF INTELLECTUAL CAPITAL DISCLOSURE 
The average quality scoring achieved for each category of IC by biotechnology companies 
cannot be considered high, with all scores, except the internal capital score for 2003, below 
0.50. These findings were not unexpected as there is currently no established and generally 
accepted framework to quantify IC information in Australia or elsewhere in the world 
(Guthrie and Petty; 2000; Guthrie et al., 2006; Yi and Davey 2010), and any quantification 
might give rise to inaccurate meaning (Abeysekera and Guthrie, 2005; Guthrie et al., 1999). . 
Comparing the minimum and maximum quality score of human capital disclosure and the 
fact that “Know-how” was the only prevalent item disclosed in this category, gives credence 
to the idea that there might be a lack of understanding of attributes in the human capital 
category. The same could be said for the internal and external capital categories, with some 
items constantly having a higher quality score throughout the period studied. It could be 
suggested that managers of biotechnology companies may lack the resources or capacity to 
collect important hard data and increase the quality of disclosures about their firm’s 
intellectual capital.  
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Amongst all the intellectual capital items that were measured, “Intellectual Property” had the 
highest quality scoring. The high incidence and quality of reporting intellectual property 
suggest that biotechnology companies place a high emphasis on patents, trademarks and 
copyrights. A possible reason for this might be due to the nature of biotechnology companies’ 
operations, since the majority of Australian biotechnology companies, at least in 2005 data, 
wereengaged in research and development-only activities (White et al., 2007) and intellectual 
property forms the core of the organisation’s asset base. This finding lends support to prior 
research that IC disclosures may be industry specific (Abdolmohammadi, 2005) and 
industries that rely more on IC disclose more information on IC (Bruggen et al., 2009, 
Kamath, 2008). “Brands”, “Customers” and “Know-how” were also frequently disclosed and 
given a relatively higher quality scoring which indicate that biotechnology firms which 
cannot legitimise their status via the “hard” assets that traditionally have symbolised 
corporate success (Guthrie et al., 2004) are more likely to report information on the 
intangibles that they possess. The deficiency of a quantitative expression of other IC items 
indicates a perceived lack of attempt to translate intellectual capital into quantifiable figures 
(Brennan, 2001; Guthrie and Petty, 2000) and that the sector might still be at the stage of 
simply understanding where the real value of a firm lies, rather than qualifying the IC 
attributes or assigning dollar values to them (Guthrie and Petty, 2000).  
Another finding of this study was a significant positive relationship between the three 
categories of intellectual capital in 2003 (refer to Table 7.1). This finding is consistent with 
the expectation that firms in earlier years had an emerging awareness of intellectual capital 
and firms which chose to disclose their intellectual capital do so by reporting all three aspects 
of intellectual capital. A possible explanation for the emerging awareness might be 
companies’ expectations that IC reporting would be an important aspect of the International 
Financial Reporting Standards (IFRS) implementation. Therefore, firms reported more 
information on IC in the 2003 annual reports in preparation for the change in reporting 
standards. However, as this was not the case when the IFRS was implemented in 2005, this 
significantly positive relationship was not noted in the latter years of 2006 and 2010.  
Moreover, the adoption of the IFRS required companies to adhere to strict reporting standards 
and fundamentally changed the way information in annual reports was presented. As a result, 
less emphasis might have been placed on intellectual capital disclosures after the 
implementation. The strict reporting standards by the IFRS also limits the disclosures that 
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companies could make in their annual reports, particularly in the recognition of intangible 
assets (AASB 138). Therefore, compliance with it could be that limited regulated disclosure 
of intangibles for financial managers, especially in the internal capital category, distracted 
their attention from voluntary reporting of extra external and human capital information. This 
explanation is further supported by the results of the Wilcoxon Signed Rank Test (refer to 
Table 8.1), where there was a significant change in the internal capital category scores 
between period 2003 and 2006, as well as between 2003 and 2010. The results showed more 
companies having a higher internal capital quality score in 2003 than in 2006 or 2010, further 
indicating a possibility that the adoption of the AASB 138 might be one reason behind the 
decrease in the disclosure of internally generated intellectual capital information. 
It was very interesting that no significant correlation between the quality of IC disclosure and 
market capitalisation or leverage was found. More specifically, the company’s size and 
leverage were not determinants for intellectual capital disclosure that biotechnology 
companies were making in their 2003, 2006 and 2010 annual reports. The lack of a 
significant relationship between size, leverage and intellectual capital disclosure quality is 
contrary to the results of several prior research studies which showed size and leverage were 
significant drivers for the frequency of ICD. 
Lastly, the results showed there was a decrease in the quality of IC disclosure over the years, 
eventhough the change was insignificant for the external and human categories of intellectual 
capital. A possible explanation for this might be that companies deemed that they had met the 
information needs of investors with respect to IC with the implementation of the IFRS. With 
the the subsequent onset of the global financial crisis, and the continuing global recession, 
companies may have arrived at the point where the cost of disclosing IC outweighs the 
benefit of doing so, therefore resulting in the insignificant decrease in IC quality disclosure 
observation. 
5.1.3 LOCATION OF INTELLECTUAL CAPITAL DISCLOSURE 
Although the items disclosed by any individual company, in general, were distributed in 
various sections of the annual report; this study showed intellectual capital items being most 
widely reported in the director’s report and business/operational sections of the annual report 
consistently throughout the 2003, 2006 and 2010 annual reports. While the disorganised 
nature of distribution suggest that there is no distinct systematic pattern of IC reporting for 
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Australian biotechnology companies, the findings of this study were similar to Guthrie et al. 
(2006) in that nearly half of all IC reported were in the “business/operational” section of the 
annual report. The count of disclosure might suggest a modest commitment in 
communicating their IC information to an external audience (Guthrie and Petty, 2000; 
Shareef and Davey, 2006). 
Lastly, a fair amount of intellectual capital disclosure was found in the chairman’s letter and 
CEO’s letter of the annual report. While the percentage of disclosure were not large, 
considering the short length of these two sections (as compared to other sections), it can be 
proposed that management do place an emphasis on intellectual capital, as evidence by them 
writing about it in their  communications. Along with the fact that the quality of ICD in this 
study was found to be low, it can be assumed that while managers place an emphasis on 
intellectual capital reporting, they may need more tools/knowledge to translate their 
understanding into high quality disclosures across all categories of intellectual capital. 
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One limitation of this study is that it only examines the annual reports of listed Australian 
biotechnology companies that were operating during the period 2003 – 2010, therefore results 
are industry and country specific and cannot be generalized. This limitation is somewhat 
mitigated by the analysis of 28 companies throughout the period under examination, rather 
than a random sample of companies in each period. 
In this study, potential limitations or bias may exist from the use of the disclosure framework. 
There is no disclosure framework comprehensive enough to measure all aspects of IC and the 
18-item framework used in this study is no exception. While the content analysis approach of 
Guthrie et al. (2004) and other scholars was used to measure the quality of intellectual capital 
disclosure, inevitably, there is some subjectivity involved when reading the annual report to 
access, classify and score information.  In addition, only 28 companies were examined in this 
study. While it is acknowledged that a bigger sample size would allow generalizability of 
results, time limitations and the availability of certain data set the sample size as such. 
7.1 SUGGESTIONS FOR FUTURE RESEARCH 
There is fair scope for extending the present work. Future research can: 1) increase the 
sample size, for instance, by selecting more companies over the time period to be studied; 
and, 2) comparing the level of intellectual capital disclosure between countries. Further 
research could apply research methods other than content analysis (e.g. questionnaires, 
survey, interviews or mixed-methods) in order to obtain a more in-depth view of how 
Australian biotechnology firms manage, measure and report their IC.  
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Table 1 Guthrie and Petty’s (2000) Modified Intangible Asset Monitor 
Internal Capital External Capital Human Capital 
Patents Brands Know-how 
Copyrights Customers Education 
Trademarks Customer loyalty Vocational qualification 
Management philosophy Company names Work-related knowledge 
Corporate culture Distribution channels Work-related competencies 
Management processes Business collaborations Entrepreneurial spirit 
Information systems Licensing agreement  
Networking systems Favourable contracts  
Financial relations Franchising agreements  
Source: Guthrie and Petty (2000) 
Table 2 Modified Intangible Asset Monitor  
1.0 Internal (Structural) Capital 
Items 
Description of items 
1.1 Intellectual Property Comprises patents, copyrights and trademarks 
1.2 Management philosophy As evidenced by vision/mission statements 
1.3 Corporate culture 
Comprises the attitudes, experiences, beliefs and 
values of the company 
1.4 Management processes Relates to processes within a company 
1.5 Information/networking systems 
Details the development, application and impact of 
information/networking systems 
1.6 Financial relations 
Relationships between the company and finance providers, 
such as banks 
2.0 External (Customer/Relational) 
Capital Items 
Description of items 
2.1 Brands Details of brands and reputation building 
2.2 Customers Information (indicators) relating to customers 
2.3 Customer loyalty Indicators of customer satisfaction/positive feedback 
2.4 Company names Names of companies collaborating with the company 
2.5 Distribution channels 
Information regarding how a company’s service and 
products reach its customers 
2.6 Business collaborations Business collaboration involving the company 
2.7 Licensing agreements 
Licensing agreements and franchising agreements held by a 
company 
3.0 Employee Competence (Human 
Capital) Items 
Description of items 
3.1 Know-how Employee knowledge 
3.2 Education Education/ongoing programmes initiated by the company 
3.3 Training Training programmes undertaken/provided by the company 
3.4 Work-related knowledge Gained “on the job” or as part of ongoing training 
3.5 Entrepreneurial spirit 
Encompasses innovativeness; proactive and reactive 
abilities; and changeability 
Source: IC Framework adopted from Guthrie et al. (2006); Description adapted from Schneider and 
Samkin (2008). 
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Table 3 Quality of disclosure scale 
Disclosure Score Description 
0 Item was not disclosed 
1 Item disclosed was purely narrative with no specific information given 
2 Item discussed in detail supported by numerical information 
3 Item was expressed in monetary form 
 
Table 4 Section of annual report where IC are disclosed 
Section Number Section of Annual Report 
1 Vision / Strategy 
2 Director’s Report 
3 Business / Operational Section 
4 Financial Section 
5 Chairman’s Letter 
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Table 5.1 Frequency of IC item disclosure based on Internal Capital, External Capital 
and Human Capital classification in 2003 
1. Internal Capital  
Frequency of 
maximum 







0 1 2 3 Total 







1.2 Management philosophy 16 12 N/A N/A 12 0.43 
1.3 Corporate culture 9 19 N/A N/A 19 0.68 
1.4 Management Processes 13 15 N/A N/A 15 0.54 
1.5 Information/networking systems 25 2 1 0 3 0.05 













2.1 Brands  1 9 6 12 27 0.68 
2.2 Customers 4 3 3 18 24 0.75 
2.3 Customer loyalty 24 2 2 0 4 0.07 
2.4 Company names 3 25 N/A N/A 25 0.89 
2.5 Distribution channels 16 7 4 1 12 0.21 
2.6 Business Collaborations 6 11 8 3 22 0.43 











3.1 Know-how 0 0 25 3 28 0.70 
3.2 Education 28 0 0 0 0 0.00 
3.3 Training 27 1 0 0 1 0.01 
3.4 Work-related knowledge 18 10 N/A N/A 10 0.12 




*Mean Quality Score: [(0*1) + (1*0)+(2*4)+(3*23)] / (3*28)  
**Weighting: Internal capital count / Total count = 98 / (98+128+40) 
N/A: Nature of item did not allow scoring of more than 1. 
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Table 5.2 Frequency of IC item disclosure based on Internal Capital, External Capital 
and Human Capital classification in 2006 
1. Internal Capital  
Frequency of 
maximum 







0 1 2 3 Total 







1.2 Management philosophy 19 9 N/A N/A 9 0.32 
1.3 Corporate culture 0 28 N/A N/A 28 1.00 
1.4 Management Processes 13 15 N/A N/A 15 0.54 
1.5 Information/networking systems 26 0 1 1 2 0.06 













2.1 Brands  2 5 8 13 26 0.71 
2.2 Customers 8 1 5 14 20 0.63 
2.3 Customer loyalty 28 0 0 0 0 0.00 
2.4 Company names 7 21 N/A N/A 21 0.75 
2.5 Distribution channels 21 5 2 0 7 0.11 
2.6 Business Collaborations 9 8 9 2 19 0.38 











3.1 Know-how 0 3 21 4 28 0.68 
3.2 Education 28 0 0 0 0 0.00 
3.3 Training 27 1 0 0 1 0.01 
3.4 Work-related knowledge 19 9 N/A N/A 9 0.11 




*Mean Quality Score: [(0*7) + (1*3)+(2*3)+(3*15)] / (3*28)  
**Weighting: Internal capital count / Total count = 94 / (94+104+38) 
N/A: Nature of item did not allow scoring of more than 1. 
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Table 5.3 Frequency of IC item disclosure based on Internal Capital, External Capital 
and Human Capital classification in 2010 
1. Internal Capital  
Frequency of 
maximum 







0 1 2 3 Total 







1.2 Management philosophy 22 6 N/A N/A 6 0.21 
1.3 Corporate culture 0 28 N/A N/A 28 1.00 
1.4 Management Processes 23 5 N/A N/A 5 0.18 
1.5 Information/networking systems 27 1 0 0 1 0.01 













2.1 Brands  2 4 5 17 26 0.77 
2.2 Customers 11 3 3 11 17 0.50 
2.3 Customer loyalty 27 0 1 0 1 0.02 
2.4 Company names 3 25 N/A N/A 25 0.89 
2.5 Distribution channels 19 7 1 1 9 0.14 
2.6 Business Collaborations 11 11 3 3 17 0.31 
2.7 Licensing agreements 18 4 2 4 10 0.24 
Total 105  0.49 







3.1 Know-how 0 0 24 4 28 0.71 
3.2 Education 27 1 0 0 1 0.01 
3.3 Training 26 1 1 0 2 0.04 
3.4 Work-related knowledge 24 4 N/A N/A 4 0.05 




*Mean Quality Score: [(0*4) + (1*1) + (2*5) + (3*18)] / (3*28)  
**Weighting: Internal capital count / Total count = 77 / (77+105+35) 
N/A: Nature of item did not allow scoring of more than 1. 
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Table 6.1 Descriptive statistics of quality measure and control variables in 2003 
Descriptives 
Quality Measure Control Variables 
IC EC HC MktCap Leverage 
n valid  28 28 28 28 28 
Mean 0.57* 0.43 0.23 48863734 0.16 
SE of mean 0.03 0.04 0.01 1.814E7 0.03 
Median 0.58 0.42 0.18 21083221 0.15 
SD 0.15 0.19 0.06 9.598E7 0.13 
Skewness 0.36 0.05 1.66 4.49 1.60 
Kurtosis -0.30 -0.51 4.40 21.87 2.48 
Actual Range               Minimum 0.3 0.11 0.18 3140800 0.01 
                                     Maximum 
Theoretical Range       Minimum 











IC: Internal Capital EC: External Capital HC: Human Capital MktCap: Market Capitalisation 
*Mean Quality Score: Sum of all internal capital items mean quality score in 2003 / Number of internal capital 
items measured [(0.92+0.43+0.68+0.54+0.05+0.76)/6].  
 
Table 6.2 Descriptive statistics of quality measure and control variables in 2006 
Descriptives 
Quality Measure Control Variables 
IC EC HC MktCap Leverage 
N valid  28 28 28 28 28 
Mean 0.49* 0.37 0.22 54256741 0.27 
SE of mean 0.03 0.03 0.01 1.628E7 0.05 
Median 0.42 0.32 0.18 22126464 0.16 
SD 0.18 0.14 0.08 8.613E7 0.29 
Skewness 0.40 0.07 0.37 2.67 2.15 
Kurtosis -0.19 -1.32 -0.20 7.33 4.95 
Actual Range               Minimum 0.17 0.16 0.09 3676867 0.03 
                                     Maximum 
Theoretical Range       Minimum 











IC: Internal Capital EC: External Capital HC: Human Capital MktCap: Market Capitalisation 
*Mean Quality Score: Sum of all internal capital items mean quality score in 2003 / Number of internal capital 
items measured [(0.64+0.32+1.00+0.54+0.06+0.63)/6].  
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Table 6.3 Descriptive statistics of quality measure and control variables in 2010 
Descriptives 
Quality Measure Control Variables 
IC EC HC MktCap Leverage 
N valid  28 28 28 28 28 
Mean 0.43* 0.36 0.22 37972117 0.55 
SE of mean 0.04 0.03 0.01 1.151E7 0.21 
Median 0.42 0.37 0.18 12734906 0.23 
SD 0.19 0.14 0.08 6.088E7 1.14 
Skewness -0.11 -0.04 3.11 2.67 4.37 
Kurtosis -0.88 -0.31 12.21 7.28 20.78 
Actual Range               Minimum 0.08 0.11 0.18 2143665 0.07 
                                     Maximum 
Theoretical Range        Minimum 











IC: Internal Capital EC: External Capital HC: Human Capital MktCap: Market Capitalisation 
*Mean Quality Score: Sum of all internal capital items mean quality score in 2003 / Number of internal capital 
items measured [(0.77+0.21+1.00+0.18+0.01+0.46)/6]. 
Table 7.1 Spearman correlation matrix of Intellectual Capital dimensions disclosure quality 
and control variables for 2003 
 IC EC HC MktCap Leverage 
 IC Correlation Coefficient 1.00 0.34 0.40
*
 0.02 -0.01 
Significance (2-tailed) . 0.08 0.03 0.92 0.97 
EC Correlation Coefficient  1.00 0.49
**
 0.26 -0.25 
Significance (2-tailed)  . 0.01 0.18 0.19 
HC Correlation Coefficient   1.00 0.10 0.06 
Sig. (2-tailed)   . 0.62 0.75 
MktCap Correlation Coefficient    1.00 0.06 
Significance (2-tailed)    . 0.77 
Leverage Correlation Coefficient     1.00 
Significance (2-tailed)     . 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
IC: Internal Capital EC: External Capital HC: Human Capital MktCap: Market Capitalisation 
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Table 7.2 Spearman correlation matrix of Intellectual Capital dimensions disclosure quality 
and control variables for 2006 
 IC EC HC MktCap Leverage 
 IC Correlation Coefficient 1.00 0.10 0.31 -0.02 -0.04 
Significance (2-tailed) . 0.63 0.11 0.94 0.86 
EC Correlation Coefficient  1.00 0.20 0.02 -0.20 
Significance (2-tailed)  . 0.32 0.92 0.31 
HC Correlation Coefficient   1.00 0.25 -0.26 
Significance (2-tailed)   . 0.21 0.18 
MktCap Correlation Coefficient    1.00 -0.37 
Significance (2-tailed)    . 0.05 
Leverage Correlation Coefficient     1.00 
Significance (2-tailed)     . 
IC: Internal Capital EC: External Capital HC: Human Capital MktCap: Market Capitalisation 
 
Table 7.3 Spearman correlation matrix of Intellectual Capital dimensions disclosure quality 
and control variables for 2010 
 IC EC HC MktCap Leverage 
 IC Correlation Coefficient 1.00 -0.02 0.23 0.23 -0.12 
Significance (2-tailed) . 0.90 0.24 0.23 0.54 
EC Correlation Coefficient  1.00 0.13 -0.10 0.29 
Significance (2-tailed)  . 0.50 0.61 0.14 
HC Correlation Coefficient   1.00 -0.10 0.23 
Significance (2-tailed)   . 0.60 0.25 
MktCap Correlation Coefficient    1.00 -0.32 
Significance (2-tailed)    . 0.10 
Leverage Correlation Coefficient     1.00 
Significance (2-tailed)     . 
IC: Internal Capital EC: External Capital HC: Human Capital MktCap: Market Capitalisation 
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 8.67 52.00 
Ties 6
c
   
Total 28   








 16.40 82.00 
Ties 6
f
   
Total 28   








 9.00 54.00 
Ties 4
i
   
Total 28   
a. 2006 Score < 2003 Score 
b. 2006 Score > 2003 Score 
c. 2006 Score = 2003 Score 
d. 2010 Score < 2006 Score 
e. 2010 Score > 2006 Score 
f. 2010 Score = 2006 Score 
g. 2010 Score < 2003 Score 
h. 2010 Score > 2003 Score 
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 9.45 94.50 
Ties 4
c
   
Total 28   








 10.71 150.00 
Ties 4
f
   
Total 28   








 13.44 121.00 
Ties 0
i
   
Total 28   
a. 2006 Score < 2003 Score 
b. 2006 Score > 2003 Score 
c. 2006 Score = 2003 Score 
d. 2010 Score < 2006 Score 
e. 2010 Score > 2006 Score 
f. 2010 Score = 2006 Score 
g. 2010 Score < 2003 Score 
h. 2010 Score > 2003 Score 
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 8.83 53.00 
Ties 12
c
   
Total 28   








 4.80 24.00 
Ties 19
f
   
Total 28   








 8.00 48.00 
Ties 13
i
   
Total 28   
a. 2006 Score < 2003 Score 
b. 2006 Score > 2003 Score 
c. 2006 Score = 2003 Score 
d. 2010 Score < 2006 Score 
e. 2010 Score > 2006 Score 
f. 2010 Score = 2006 Score 
g. 2010 Score < 2003 Score 
h. 2010 Score > 2003 Score 
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Count 2 70 57 42 25 11 67 274 
Percentage % 0.73 25.55 20.80 15.33 9.12 4.01 24.45 100 
External capital 
Count 0 99 122 17 55 34 60 387 
Percentage % 0 25.58 31.52 4.39 14.21 8.79 15.50 100 
Human capital 
Count 0 51 19 0 6 8 12 96 
Percentage % 0 53.123 19.79 0 6.25 8.33 12.50 100 
All IC disclosure 
Sum 2 220 198 59 86 53 139 757 
Percentage % 0.26 29.06 26.16 7.79 11.36 7.00 18.36 100 
 















































































Count 5 89 71 19 16 6 35 241 
Percentage % 2.07 36.93 29.46 7.88 6.64 2.49 14.52 100 
External capital 
Count 0 113 107 12 44 43 52 371 
Percentage % 0 30.46 28.84 3.23 11.86 11.59 14.02 100 
Human capital 
Count 0 77 22 0 8 3 6 116 
Percentage % 0 66.38 18.97 0 6.90 2.59 5.17 100 
All IC disclosure 
Sum 5 279 200 31 68 52 93 728 
Percentage % 0.69 38.32 27.47 4.26 9.34 7.14 12.77 100 
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Count 1 86 20 20 26 1 121 275 
Percentage % 0.36 31.27 7.27 7.27 9.45 0.36 44.00 100 
External capital 
Count 0 58 54 28 80 10 39 269 
Percentage % 0 21.56 20.07 10.41 29.74 3.72 14.50 100 
Human capital 
Count 0 62 9 0 8 0 9 88 
Percentage % 0 70.45 10.23 0 9.09 0 10.23 100 
All IC disclosure 
Sum 1 206 83 48 114 11 169 632 
Percentage % 0.16 32.59 13.13 7.59 18.04 1.74 26.74 100 
 
